Sometimes respond to medical therapy with a 5-reductase inhibitor.Ħ. Hematuria may be associated with prostatic vascularity and may There is no convincing evidence that UTI in the aging male population isĪssociated with either PVR urine or BOO. Presence of UTI and Hematuria measuring clinicalappearance and urinalysis Therefore improvement of an OAB is not a standardoutcome measure in clinical trials.ĥ. The presence of an OAB does not reliably predict response to medical orsurgical treatment. Presence of Bladder Overactivty measuring detrussorsĭefinition : development of a detrusor contraction exceeding 15 cm H2O ata bladder volume less than 300 mL (Jepsen and Bruskewitz, 2000). Insignificant baseline PVR urine volumes potentially undermining therelevance of most trials to real world practice.Ĥ.
Majority of BPH clinical trials exclude subjects with high baseline PVRĪmount (>300 mL) because of the potential risks of randomization to aplacebo or ineffective treatment group Bladder emptying performance measuring PVR volumeusing TAUS The reporting of PFR has been standardized but the clinical significance ofthe changes in PFR cannot be defined, owing to the lack of correlationswith relevant clinical, physiologic, or biochemical outcomes. Uroflowmetry is a noninvasive, inexpensive, indirect indicator of urinaryperformances measure of BOO. Degree of BOO measuring PFR using Uroflowmetry The group mean changes in AUASI for subjects rating theirimprovement as markedly, moderately, or slightly improved, unchanged,or worse.Ģ. The clinical significance of changes in the AUASI score at baseline andafter 3 months of treatment were reported by Barry and colleagues Degree of Symptoms measuring LUTS using IPSS/AUASI
Determine Clinical End Points in BPH Therapyĭeterioration of symptomsFuture episodes of gross hematuriaĢ.
Textbook ReadingCampbell-Walsh Urology 10thEditionġ. A L D I L L A W A H Y U R A H M A D I A N